Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2296-2302

  Forrester, Elizabeth ^a   Chytil, Anna ^a,b   Bierie, Brian ^a   Aakre, Mary ^a,b   Gorska, Agnieszka E ^a,b   Sharif Afshar, Ali Reza ^a   Muller, William J ^c   Moses, Harold L ^a,b  

^a Department of Cancer Biology ^*  (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; VIRUS MIDDLE T ANTIGEN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CONTROLLED STUDY; LUNG METASTASIS; MAMMARY GLAND; METASTASIS; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; RECEPTOR GENE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HYPERPLASIA; LUNG NEOPLASMS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PULMONARY ALVEOLI; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSGENES;

EID: 16844373628     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3272     Document Type: Article

References (30)

1. Moses HL. TGF-β regulation of epithelial cell proliferation. Mol Reprod Dev 1992;32:179-84.
2. Sun L. Tumor-suppressive and promoting function of transforming growth factor β. Front Biosci 2004;9:1925-35.
3. Pierce DF Jr, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor β 1 transgene expression. Proc Natl Acad Sci U S A 1995;92:4254-8.
4. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominant-negative interference of the transforming growth factor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ 1998;9:229-38.
5. Gorska AE, Shyr YU, Aakre M, Bhowmick N, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol 2003;163:1539-49.
6. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[α]-anthracene. Cancer Res 1997;57:5564-70.
7. Gobbi H, Jensen RA, Simpson JF, et al. Loss of expression of transforming growth factor β type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology 2000;36:168-77.
8. Takenoshita SMA, Tani M, Osawa H, et al. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-β type II receptor gene in sporadic human breast cancers. Oncol Rep 1998;5:367-71.
9. Gobbi H, Simpson JF, Plummer WD, Schuyler PA, Arteaga CL, Page DL. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999;91:2096-101.
10. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer. Tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000;2:125-32.
11. Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
12. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-9.
13. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607-15.
14. Chytil A, Magnuson MA, Wright CV, Moses HL. Conditional inactivation of the TGF-β type II receptor using Cre:Lox. Genesis 2002;32:73-5.
15. White DE, Kurpios NA, Zuo D, et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159-70.
16. Andrechek ER, Hardy WR, Siegel PM, et al. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A 2000;97:3444-9.
17. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
18. Joseph H, Gorska AE, Sohn P, Moses HL, Serra R. Overexpression of a kinase-deficient transforming growth factor-β type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell 1999;10:1221-34.
19. Wagner KU, McAllister K, Ward T, et al. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 2001;10:545-53.
20. Law BK, Norgaard P, Gnudi L, et al. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J Biol Chem 1999;274:4743-8.
21. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999;21:70-1.
22. Tu WH, Thomas TZ, Masumori N, et al. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia 2003;5:267-77.
23. Biswas S, Chytil A, Washington K, et al. Transforming growth factor β receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004;64:4687-92.
24. Akhurst RJ, Derynck R. TGF-β signaling in cancer: a double-edged sword. Trends Cell Biol 2001:11:S44-51.
25. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor β in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004;100:2281-91.
26. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118-22.
27. Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2002;2:46-53.
28. Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58:3101-4.
29. Watanabe T, Wu T, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
30. 1 arrest, p53, and Rb. Cancer Res 1996;56:3645-50.